Steve Bagshaw, chief executive officer at FUJIFILM Diosynth Biotechnologies, offers some insight into the ever changing CDMO landscape and the future of medicine. Mr. Bagshaw is an industry thought leader and an advocate of the Biotechnology Industry.
Q: Fujifilm Diosynth Biotechnologies has been expanding and making big announcements in the past year. Can you talk about how this growth is shaping your long-term vision as a contract development and manufacturing organization (CDMO)?
We are seeing the benefits of long-term investment. In 2013, we launched our Apollo mammalian expression technology, which was the end result of an in-house innovation program. The Apollo technology has been incredibly successful. As a leading CDMO, our process development is one of our key differentiators. We want to maintain and expand our technical leadership long term by investing with the addition of new state of the art laboratories.
Login to read the full PDF of this article.